Home > Newsletters > RxTrials Institute Drug Pipeline Alert > ArQule Begins Enrollment in Lung Cancer Trial
RxTrials Institute Drug Pipeline Alert
March 19, 2008 | Vol. 6 No. 12
ArQule Begins Enrollment in Lung Cancer Trial
ArQule has begun its Phase I/II clinical trial program of ARQ 197 administered in combination with Tarceva in patients with advanced nonsmall cell lung cancer (NSCLC).
The NSCLC program consists of two trials, the first of which will determine the safety, tolerability and Phase II dose of ARQ 197 when administered in combination with Tarceva (erlotinib).
Investigators also will evaluate the pharmacokinetic profile and assess the preliminary antitumor activity of this combination therapy.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.